# Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169

> **NCT04150224** · PHASE1 · COMPLETED · sponsor: **Nearmedic Plus LLC** · enrollment: 60 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** PBTZ169 640 mg OD
- **DRUG:** PBTZ169 640 mg BiD
- **DRUG:** PBTZ169 960 mg SD
- **DRUG:** PBTZ169 1280 mg SD
- **DRUG:** PBTZ169 1280 mg MD

## Key facts

- **NCT ID:** NCT04150224
- **Lead sponsor:** Nearmedic Plus LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-03
- **Primary completion:** 2018-11-23
- **Final completion:** 2019-02-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04150224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04150224, "Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04150224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*